Cellect Biotechnology Ltd. (NASDAQ:APOP) and BioTime Inc. (NYSEAMERICAN:BTX) compete with each other in the Biotechnology sector. We will analyze and compare their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellect Biotechnology Ltd.	N/A	0.00	N/A	-0.85	0.00
BioTime Inc.	4.99M	38.33	45.99M	-0.58	0.00

Table 1 demonstrates Cellect Biotechnology Ltd. and BioTime Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Cellect Biotechnology Ltd. and BioTime Inc.

	Net Margins	Return on Equity	Return on Assets
Cellect Biotechnology Ltd.	0.00%	0%	0%
BioTime Inc.	-921.64%	-54.6%	-51%

Insider & Institutional Ownership

Institutional investors held 0% of Cellect Biotechnology Ltd. shares and 45.1% of BioTime Inc. shares. Insiders held roughly 54.73% of Cellect Biotechnology Ltd.’s shares. Insiders Comparatively, held 0.8% of BioTime Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellect Biotechnology Ltd.	-3.64%	-55.62%	-69.71%	-79.8%	-85.09%	-49.52%
BioTime Inc.	-2.5%	-17.02%	-2.88%	-40.61%	-42.59%	28.15%

For the past year Cellect Biotechnology Ltd. has -49.52% weaker performance while BioTime Inc. has 28.15% stronger performance.

Summary

BioTime Inc. beats Cellect Biotechnology Ltd. on 5 of the 9 factors.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.